Hostname: page-component-7c8c6479df-8mjnm Total loading time: 0 Render date: 2024-03-29T13:35:14.345Z Has data issue: false hasContentIssue false

Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: Performances of immunochemical colorectal cancer screening

Published online by Cambridge University Press:  08 January 2010

Célia Berchi
Affiliation:
University of Caen and ERI3 INSERM
Lydia Guittet
Affiliation:
University of Caen and ERI3 INSERM
Véronique Bouvier
Affiliation:
University of Caen and ERI3 INSERM
Guy Launoy
Affiliation:
University of Caen and ERI3 INSERM

Abstract

Background: Most industrialized countries, including France, have undertaken to generalize colorectal cancer screening using guaiac fecal occult blood tests (G-FOBT). However, recent researches demonstrate that immunochemical fecal occult blood tests (I-FOBT) are more effective than G-FOBT. Moreover, new generation I-FOBT benefits from a quantitative reading technique allowing the positivity threshold to be chosen, hence offering the best balance between effectiveness and cost. We aimed at comparing the cost and the clinical performance of one round of screening using I-FOBT at different positivity thresholds to those obtained with G-FOBT to determine the optimal cut-off for I-FOBT.

Methods: Data were derived from an experiment conducted from June 2004 to December 2005 in Calvados (France) where 20,322 inhabitants aged 50–74 years performed both I-FOBT and G-FOBT. Clinical performance was assessed by the number of advanced tumors screened, including large adenomas and cancers. Costs were assessed by the French Social Security Board and included only direct costs.

Results: Screening using I-FOBT resulted in better health outcomes and lower costs than screening using G-FOBT for thresholds comprised between 75 and 93 ng/ml. I-FOBT at 55 ng/ml also offers a satisfactory alternative to G-FOBT, because it is 1.8-fold more effective than G-FOBT, without increasing the number of unnecessary colonoscopies, and at an extra cost of €2,519 per advanced tumor screened.

Conclusions: The use of an automated I-FOBT at 75 ng/ml would guarantee more efficient screening than currently used G-FOBT. Health authorities in industrialized countries should consider the replacement of G-FOBT by an automated I-FOBT test in the near future.

Type
ASSESSMENTS
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Allison, JE, Tekawa, IS, Ransom, LJ, et al. A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med. 1996;334:155159.CrossRefGoogle ScholarPubMed
2. Belot, A, Grosclaude, P, Bossard, N, et al. Cancer incidence and mortality in France over the period 1980–2005. Rev Epidemiol Sante Publique. 2008;56:159175.CrossRefGoogle ScholarPubMed
3. Berchi, C, Bouvier, V, Réaud, JM, et al. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 2004;13:227238.CrossRefGoogle ScholarPubMed
4. Bouvier, V, Réaud, JM, Gignoux, G, et al. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados department, France. Eur J Health Econ. 2003;2:102106.CrossRefGoogle Scholar
5. Castiglione, G, Sala, P, Ciatto, S, et al. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur J Cancer Prev. 1994;3:399405.CrossRefGoogle ScholarPubMed
6. Chen, LS, Liao, CS, Chang, SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen. 2007;14:191199.CrossRefGoogle ScholarPubMed
7. Clerc, L, Jooste, V, Lejeune, C, et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ. 2008;9:361367.CrossRefGoogle ScholarPubMed
8. Gatto, NM, Frucht, H, Sundararajan, V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: A population-based study. J Natl Cancer Inst. 2003;95:230236.CrossRefGoogle ScholarPubMed
9. Guittet, L, Bouvier, V, Mariotte, N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210214.CrossRefGoogle Scholar
10. Guittet, L, Bouvier, V, Mariotte, N, et al. Performances of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer. 2009;125:11271133.CrossRefGoogle ScholarPubMed
11. Hardcastle, JD, Chamberlain, JO, Robinson, MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:14721477.CrossRefGoogle ScholarPubMed
12. Kronborg, O, Fenger, C, Olsen, J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:14671471.CrossRefGoogle ScholarPubMed
13. Mandel, JS, Bond, JH, Church, TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:13651371.CrossRefGoogle ScholarPubMed
14. Nakama, H, Zhang, B, Zhang, Y. Evaluation of the optimum threshold in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 2001;37:398401.CrossRefGoogle Scholar
15. Saito, H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res. 1996;87:10111024.CrossRefGoogle ScholarPubMed
16. Sieg, A, Hertel, A, John, MR, et al. Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. Eur J Cancer Prev. 1998;7:279285.CrossRefGoogle ScholarPubMed
17. Zappa, M, Castiglione, G, Paci, E, et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: The district of Florence experience. Int J Cancer. 2001;92:151154.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Supplementary material: File

Berchi et al. supplementary material

Figures 1 and 2

Download Berchi et al. supplementary material(File)
File 90.1 KB